Concepedia

Matthew L. Hemming

ML

Statistics

Publications

23

Citations

2.2K

H-Index

20

Active since

1996

Affiliations

Harvard University(Current)

Brigham and Women's Hospital

Dana-Farber Cancer Institute

University of Pennsylvania

Dana-Farber Brigham Cancer Center

Matthew L. Hemming is an author at Harvard University specializing in medicine, oncology, and molecular oncology.

Publications per year

1996–2024

23

Publications

23

Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor

Matthew L. Hemming, Dennis J. Selkoe · Journal of Biological Chemistry · 2005 · 336 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs

William Flavahan, Yotam Drier, Sarah E. Johnstone et al. · Nature · 2019 · 260 citations

Medicine, Genetics, Molecular Genetics +10

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

Gerard L. Brien, David Remillard, Junwei Shi et al. · eLife · 2018 · 216 citations · Full text

Medicine, Molecular Biology, Oncology +17

Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics

Matthew L. Hemming, Joshua E. Elias, Steven P. Gygi et al. · PLoS ONE · 2009 · 193 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity

Christopher J. Winrow, Matthew L. Hemming, Duane M. Allen et al. · Nature Genetics · 2003 · 176 citations

Pharmacy, Neuroscience, Toxicology +14

1–5 of 23